GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT05999799
- Locations
- 🇹🇭
GSK Investigational Site, Pathumthani, Thailand
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
Phase 1
Withdrawn
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05999708
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
Phase 1
Completed
- Conditions
- Herpes Simplex
- Interventions
- Biological: HSVTI Formulation 1Biological: HSVTI Formulation 2Biological: Placebo
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT05989672
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
Phase 1
Completed
- Conditions
- Influenza, Human
- Interventions
- Biological: FLU Q-PAN H5N8 375_BBiological: FLU Q-PAN H5N8 375_ABiological: FLU Q-PAN H5N8 750_BBiological: FLU Q-PAN H5N8 750_A
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 518
- Registration Number
- NCT05975840
- Locations
- 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboBiological: mRNA-CR-04 vaccine 30μgBiological: mRNA-CR-04 vaccine 100μgBiological: mRNA-CR-04 vaccine 3μgBiological: mRNA-CR-04 vaccine 10μg
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT05972993
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
Phase 3
Completed
- Conditions
- Respiratory Syncytial VirusesRespiratory Syncytial Virus Infections
- Interventions
- Biological: HZ/su vaccine
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 530
- Registration Number
- NCT05966090
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Canada
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Phase 2
Active, not recruiting
- Conditions
- SARS-CoV-2
- Interventions
- Biological: CV0701 Bivalent High doseBiological: CV0701 Bivalent Medium doseBiological: CV0701 Bivalent Low doseBiological: Control vaccineBiological: CV0801 MonovalentBiological: CV0601 Monovalent High dose
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 675
- Registration Number
- NCT05960097
- Locations
- 🇦🇺
GSK Investigational Site, Tarragindi, Australia
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
Phase 2
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 387
- Registration Number
- NCT05921903
- Locations
- 🇪🇸
GSK Investigational Site, Santander, Spain
A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Standard of care
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT05917288
- Locations
- 🇨🇳
GSK Investigational Site, Suzhou, China
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
Phase 3
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1113
- Registration Number
- NCT05879107
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain